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Abstract
Background: Nintedanib is an approved therapy for idiopathic pulmonary fibrosis (IPF). Some patients treated with
nintedanib experience weight loss. Exploratory data suggest that low body mass index or weight loss are
associated with worse outcomes in patients with IPF. We investigated whether BMI at baseline or weight loss over
52 weeks was associated with FVC decline, or influenced the effect of nintedanib, in patients with IPF.
Methods: Using pooled data from the two INPULSIS trials, we analysed the rate of decline in FVC (mL/yr) over 52
weeks in patients treated with nintedanib and placebo in subgroups by baseline BMI (< 25; ≥25 to < 30; ≥30 kg/
m2) and by weight loss over 52 weeks (≤5; > 5%) using random coefficient regression.
Results: In the placebo group, the mean rate of FVC decline over 52 weeks was numerically greater in patients with
lower baseline BMI (− 283.3 [SE 22.4], − 207.9 [20.9] and − 104.5 [21.4] in patients with BMI < 25 kg/m2, ≥25 to < 30
kg/m2 and ≥ 30 kg/m2, respectively). Nintedanib reduced the rate of FVC decline versus placebo in all subgroups by
BMI, with a consistent treatment effect across subgroups (interaction p = 0.31). In the placebo group, the mean rate
of FVC decline was numerically greater in patients with > 5% than ≤5% weight loss over 52 weeks (− 312.7 [SE 32.2]
versus − 199.5 [SE 14.4] mL/year). Nintedanib reduced the rate of FVC decline versus placebo in both subgroups by
weight loss, with a greater treatment effect in patients with > 5% weight loss (interaction p = 0.0008). The adverse
event profile of nintedanib was similar across subgroups.
Conclusions: In patients with IPF, lower BMI and weight loss may be associated with faster decline in FVC.
Nintedanib reduces the rate of FVC decline both in patients who lose weight on treatment and those who do not.
Trial registration: ClinicalTrials.gov; Nos. NCT01335464 and NCT01335477; URL: www.clinicaltrials.gov.
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Introduction
Idiopathic pulmonary fibrosis (IPF) is an interstitial lung
disease characterised by progressive loss of lung function
[1]. IPF mainly affects individuals over the age of 60
years and is typically associated with several comorbidi-
ties [2]. The clinical course of IPF is variable but ultim-
ately fatal, with a median survival in untreated patients
of approximately 3 years from diagnosis [3]. A decline in
forced vital capacity (FVC) is an established predictor of
mortality in patients with IPF [4].
Some studies have suggested that lower body mass
index (BMI) [5–7] or weight loss [8, 9] may be associ-
ated with worse prognosis in patients with IPF, although
this has not been observed in all studies [10–12]. Large
weight loss in obese individuals has been associated with
an improvement in FVC [13] and smaller weight reduc-
tions with an improvement in FVC in the general popu-
lation [14]. A retrospective analysis of data from 210
patients with IPF found a greater rate of FVC decline
among patients with weight loss > 5% than ≤5% over 1
year [8]. However, it remains unclear whether small
weight reductions are associated with changes in FVC in
patients with IPF.
Nintedanib is a tyrosine kinase inhibitor approved for
the treatment of IPF. In the two Phase III 52-week
INPULSIS trials, nintedanib reduced the rate of decline
in FVC in patients with mild or moderate impairment in
lung function by approximately 50%, with an adverse
event profile characterised mainly by gastrointestinal
events [15]. Weight loss recorded as an adverse event
was more frequently reported in patients treated with
nintedanib than placebo [15]. We used pooled data from
the INPULSIS trials to investigate whether BMI at base-
line or weight loss over 52 weeks was associated with
changes in FVC or influenced the treatment effect of
nintedanib.
Methods
Trial design and participants
The INPULSIS trials (NCT01335464 and NCT01335477)
were two randomised, double-blind, placebo-controlled
trials of nintedanib in patients with IPF, performed at 205
sites in 24 countries. Eligibility criteria for the INPULSIS
trials have been described [15]. Briefly, the participants
were aged ≥40 years, with a diagnosis of IPF, FVC ≥50%
predicted and diffusing capacity of the lungs for carbon
monoxide (DLco) 30–79% predicted.
Patients were randomised 3:2 to receive nintedanib
150 mg twice daily or placebo for 52 weeks, with a
follow-up visit 4 weeks after treatment discontinuation.
Treatment interruption and dose reduction to 100 mg
twice daily were allowed to manage adverse events. After
an adverse event had resolved, the dose could be in-
creased back to 150 mg twice daily. Patients who
discontinued study drug prematurely were asked to at-
tend all scheduled visits and undergo all examinations as
originally planned. FVC was measured at baseline and at
weeks 2, 4, 6, 12, 24, 36, and 52 using sponsor-provided
spirometers. Weight was measured at baseline and at
weeks 2, 4, 6, 12, 24, 36, and 52.
Outcomes
The pre-specified subgroup analyses of the INPULSIS
trials have been reported [15, 16]. Here, we describe
post-hoc analyses of efficacy and safety outcomes in sub-
groups by BMI at baseline and by weight loss over 52
weeks. Efficacy outcomes assessed were the annual rate
of decline in FVC (mL/year); absolute change from base-
line in FVC (mL); absolute change from baseline in FVC
% predicted; time to first investigator-reported acute ex-
acerbation; absolute change from baseline in St. George’s
Respiratory Questionnaire (SGRQ) total score; time to
absolute decline in FVC ≥10% predicted or death; and
time to death, all over 52 weeks. An acute exacerbation
was defined based on worsening or development of dys-
pnoea and the appearance of new abnormalities on
high-resolution computed tomography (HRCT), with the
exclusion of known causes of acute worsening in respira-
tory function [15]. The SGRQ is a self-administered
questionnaire, comprising three domains (symptoms, ac-
tivity, impact), which assesses health-related quality of
life in patients with respiratory disease on a scale of 0 to
100 [17]. Safety was assessed based on adverse events re-
ported by the investigators (irrespective of causality)
with onset after the first dose and up to 4 weeks after
the last dose of study drug, which were coded according
to preferred terms in the Medical Dictionary for Regula-
tory Activities (MedDRA) version 20.1. Reductions in
weight reported by the investigators as adverse events
(based on perceived clinical relevance rather than a de-
fined degree of weight loss) were coded under the pre-
ferred term “weight decreased”.
Statistical analysis
Analyses were conducted using data from patients who
received ≥1 dose of nintedanib or placebo. In the pri-
mary analysis, the annual rate of decline in FVC (mL/
year) was analysed using a random coefficient regression
model (with random slopes and intercepts) with fixed ef-
fects for trial, treatment, sex, age and height and random
effect of patient-specific intercept and time. To assess
the effect of BMI at baseline or weight loss on the treat-
ment effect of nintedanib, we repeated the original
analyses with the addition of covariates for race (White;
Asian; Black/African-American) and either BMI at base-
line (< 25; ≥25 to < 30; ≥30 kg/m2) or weight loss over
52 weeks (weight gain or ≤ 5% weight loss; > 5% weight
loss) to the model. In addition, we assessed outcomes in
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subgroups by BMI at baseline (< 25 kg/m2; ≥25 to < 30
kg/m2; ≥30 kg/m2) and by weight loss over 52 weeks
(weight gain or ≤ 5% weight loss; > 5% weight loss).
Weight loss ≤5% or > 5% over 52 weeks was assessed
based on the annual rate of decline in weight analysed
using a random coefficient regression model with fixed
effects for trial, treatment, sex, age and height and ran-
dom effect of patient specific-intercept and time. We
also analysed the annual rate of decline in FVC (mL/
year) in subgroups based on BMI below and at least the
median at baseline, and in subgroups by weight loss over
52 weeks (weight gain/no weight loss; > 0 to ≤5% weight
loss; > 5 to ≤10% weight loss; > 10% weight loss) based
on the change from baseline in weight at week 52 (or, if
no week 52 measurement was available, the last meas-
urement after baseline but before week 52). In analyses
of the annual rate of decline in FVC, the term subgroup
and the interaction terms treatment-by-subgroup, time-
by-subgroup and treatment-by-time-by-subgroup were
included in the model. The model allowed for missing
data, assuming that they were missing at random; miss-
ing data were not imputed. The interaction p-values are
an indicator of the difference in the effect of nintedanib
versus placebo among the subgroups. The other statis-
tical analyses are described in Supplemental Appendix 1.
Analyses were not adjusted for multiplicity. Adverse
events are presented descriptively.
Results
Patients
A total of 638 patients with IPF were treated with ninte-
danib and 423 with placebo. Baseline characteristics
were balanced between the nintedanib and placebo
groups. Most (79.3%) of the participants were male.
Mean (SD) age at baseline was 66.8 (8.0) years, weight
was 79.0 (16.6) kg, BMI was 27.9 (4.6) kg/m2, and FVC
% predicted was 79.6 (17.8).
Analyses based on BMI at baseline
At baseline, 307 (28.9%), 453 (42.7%) and 301 (28.4%)
patients had BMI < 25 kg/m2, ≥25 to < 30 kg/m2 and ≥
30 kg/m2, respectively. Compared with patients with
BMI ≥30 kg/m2, greater proportions of patients with
BMI < 25 or ≥ 25 to < 30 kg/m2 were of Asian race, and
greater proportions with BMI < 25 kg/m2 had never
smoked (Supplemental Table 1). Low correlation was
observed between BMI at baseline and FVC (mL) at
baseline (Supplemental Figure 1).
Low correlation was observed between BMI at baseline
and the rate of decline in FVC over 52 weeks (Supple-
mental Figure 1). However, in the placebo group, the
mean rate of decline in FVC (mL/year) over 52 weeks
was numerically greater in patients with BMI < 25 kg/m2
(− 283.3 [SE 22.4]) than BMI ≥25 to < 30 kg/m2 (− 207.9
[20.9]) or BMI ≥30 kg/m2 (− 175.7 [27.0]) (Figs. 1 and 2;
Fig. 1 Annual rate of decline in FVC (mL/year) assessed over 52 weeks by BMI at baseline
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Table 1). In the nintedanib group, the mean rate of de-
cline in FVC over 52 weeks was similar across subgroups
with baseline BMI < 25 kg/m2, ≥25 to < 30 kg/m2 and ≥
30 kg/m2 (mL/year) (− 142.9 [SE 20.8], − 104.0 [16.0]
and − 104.5 [21.4] mL/year, respectively) (Figs. 1 and 2;
Table 1). Nintedanib reduced the annual rate of decline
in FVC versus placebo in all the subgroups by baseline
BMI with a treatment effect that was numerically greater
in patients with lower BMI, but the p-value for
treatment-by-time-by-subgroup interaction did not indi-
cate heterogenous treatment effects across the sub-
groups (p = 0.31). Similar results were observed when
the rate of decline in FVC was analysed in subgroups by
baseline BMI above and below the median (27 kg/m2)
(Supplemental Table 2). When BMI at baseline (< 25;
≥25 to < 30; ≥30 kg/m2) and race were included in the
model analysing the rate of decline in FVC (mL/year)
over 52 weeks, the difference between treatment groups
was consistent with the original analysis (Supplemental
Table 3).
The mean increase (worsening) in SGRQ total score at
week 52 in placebo-treated patients was numerically
greater in patients with baseline BMI < 25 kg/m2 than
≥25 to < 30 kg/m2 and ≥ 30 kg/m2 (7.0 versus 4.5 and
4.2, respectively). The proportions of placebo-treated pa-
tients who had an investigator-reported acute exacerba-
tion was similar across these subgroups (7.9, 7.7 and
7.0%, respectively), while the proportions of patients
who died was numerically greater in patients with base-
line BMI < 25 kg/m2 than ≥25 to < 30 kg/m2 or ≥ 30 kg/
m2 (10.7% versus 6.0 and 7.0%, respectively).
Differences between the nintedanib and placebo
groups in absolute changes from baseline in FVC (mL
and % predicted) and change in SGRQ total score were
numerically greater in patients with BMI < 25 kg/m2
than ≥25 to < 30 kg/m2 or ≥ 30 kg/m2, but the p-values
for treatment-by-subgroup interaction did not indicate
heterogenous treatment effects across the subgroups
(Table 1). Differences between the nintedanib and pla-
cebo groups in the proportion of patients with an abso-
lute decline in FVC ≥10% predicted or death, and the
proportion of patients who died were consistent across
subgroups by BMI at baseline (Table 1).
Analyses based on weight loss over 52 weeks
The mean (SE) annual rate of decline in weight over 52
weeks was − 3.3 (0.2) kg/year and − 1.5 (0.2) kg/year in
the nintedanib and placebo groups, respectively. Based
on the annual rate of decline in weight, in the nintedanib
group, 397 (62.2%) patients had weight gain or ≤ 5%
weight loss and 241 (37.8%) had > 5% weight loss over
52 weeks, and in the placebo group, 338 (79.9%) had
weight gain or ≤ 5% weight loss and 85 (20.1%) had > 5%
weight loss over 52 weeks. Compared with patients with
Fig. 2 Change from baseline in FVC (mL) over 52 weeks by BMI at baseline
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Fig. 3 Annual rate of decline in FVC (mL/year) over 52 weeks by weight loss over 52 weeks
Fig. 4 Change from baseline in FVC (mL) over 52 weeks by weight loss over 52 weeks
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≤5% weight loss, patients with > 5% weight loss over 52
weeks had a greater proportion of females, lower mean
FVC and DLco % predicted at baseline, and higher
(worse) mean SGRQ total score at baseline (Supplemen-
tal Table 4).
In the placebo group, the rate of decline in FVC (mL/
year) was numerically greater in patients with > 5% than
≤5% weight loss over 52 weeks (− 312.7 [SE 32.2] versus
− 199.5 [SE 14.4] mL/year) (Figs. 3 and 4; Table 2), as
was the mean increase (worsening) in SGRQ total score
at week 52 (13.6 versus 3.0). In the placebo group, the
proportion of patients who had an acute exacerbation
was numerically greater (11.8% versus 6.5%), but the
proportion of patients who died was numerically lower
(5.9% versus 8.3%), in patients with > 5% than ≤5%
weight loss.
When weight loss over 52 weeks and race were in-
cluded in the model analysing the annual rate of decline
in FVC (mL/year), the difference between nintedanib
and placebo was consistent with the original analysis
(Supplemental Table 3). Nintedanib reduced the annual rate
of decline in FVC versus placebo both in patients with ≤5
and > 5% weight loss over 52weeks, with a greater effect in
patients with > 5% than ≤5% weight loss (p = 0.0008 for
treatment-by-time-by-subgroup interaction) (Figs. 3 and 4;
Table 2). Nintedanib also had a greater effect on the annual
rate of decline in FVC in patients with greater weight loss
based on the change from baseline in weight at week 52 (no
Table 2 Outcomes in subgroups of patients by weight loss over 52 weeksa
Weight loss ≤ 5% Weight loss > 5%
Nintedanib
(n = 397)
Placebo
(n = 338)
Nintedanib
(n = 241)
Placebo
(n = 85)
Annual rate of decline in FVC (mL/year)
assessed over 52 weeks
− 121.0 (13.2) −199.5 (14.4) − 103.0 (19.5) −312.7 (32.2)
Difference versus placebo (95% CI) 78.5 (40.1, 116.9) 209.6 (135.7, 283.6)
p-value for treatment-by-time-by-subgroup
interaction
0.0008
Absolute change from baseline in FVC (mL)
over 52 weeks
− 114.2 (14.6) − 197.3 (15.9) −94.4 (20.1) − 278.9 (33.4)
Difference versus placebo (95% CI) 83.1 (40.8, 125.4) 184.5 (107.8, 261.2)
p-value for treatment-by-subgroup
interaction
0.54
Absolute change from baseline in FVC %
predicted over 52 weeks
−3.3 (0.4) −5.6 (0.5) −3.1 (0.6) −9.1 (1.0)
Difference versus placebo (95% CI) 2.3 (1.1, 3.5) 6.0 (3.6, 8.4)
p-value for treatment-by-subgroup
interaction
0.54
Absolute change from baseline in SGRQ
total score over 52 weeks
3.3 (0.8) 3.0 (0.9) 4.2 (1.1) 13.6 (1.7)
Difference versus placebo (95% CI) 0.3 (−2.1, 2.7) −9.5 (−13.5, −5.4)
p-value for treatment-by-subgroup
interaction
0.20
Patients with absolute decline in FVC ≥10%
predicted or death at week 52, n (%)
100 (25.2) 128 (37.9) 73 (30.3) 47 (55.3)
HR (95% CI) 0.62 (0.48, 0.81) 0.51 (0.35, 0.73)
p-value for treatment-by-subgroup
interaction
0.32
Patients with ≥1 acute exacerbation of IPF
over 52 weeks
14 (3.5) 22 (6.5) 17 (7.1) 10 (11.8)
HR (95% CI) 0.53 (0.27, 1.04) 0.63 (0.29, 1.38)
p-value for treatment-by-subgroup
interaction
0.84
Deaths over 52 weeks, n (%) 19 (4.8) 28 (8.3) 16 (6.6) 5 (5.9)
HR (95% CI) 0.58 (0.32, 1.04) 1.24 (0.45, 3.41)
p-value for treatment-by-subgroup
interaction
0.23
Changes from baseline are adjusted mean (SE). HR Hazard ratio. aBased on the annual rate of decline in weight
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weight loss, > 0 to ≤5% weight loss, > 5 to ≤10% weight loss
and > 10% weight loss) (p = 0.0017 for treatment-by-time-by-
subgroup interaction) (Supplemental Figure 2). Differences
between the nintedanib and placebo groups in change in
SGRQ total score and the proportion of patients with an ab-
solute decline in FVC ≥10% predicted or death were numer-
ically greater in patients with > 5% than ≤5% weight loss, but
the p-values for treatment-by-subgroup interaction did not
indicate heterogenous treatment effects between the sub-
groups (Table 2).
Adverse events in subgroups by BMI at baseline and
weight loss over 52 weeks
In both the nintedanib and placebo groups, the propor-
tions of patients with adverse events of decreased appe-
tite, weight decrease, and progression of IPF were
greater in patients with lower baseline BMI and in pa-
tients with > 5% than ≤5% weight loss over 52 weeks
(Tables 3 and 4). The proportion of patients with diar-
rhoea adverse events was greater in those with > 5% than
≤5% weight loss (Table 4). The adverse event profile of
nintedanib was similar across subgroups by baseline
BMI and weight loss over 52 weeks, with gastrointestinal
adverse events reported more frequently in patients
treated with nintedanib than placebo (Tables 3 and 4).
Discussion
These post-hoc analyses of pooled data from the INPUL-
SIS trials suggest that the rate of decline in FVC over 52
weeks was greater in untreated patients with IPF who
had lower BMI at baseline, and in patients who had > 5%
weight loss during the trials. The effect of nintedanib on
reducing the rate of FVC decline was numerically more
pronounced in patients with lower BMI at baseline and
in patients who had > 5% weight loss during the trials.
The rate of decline in FVC in nintedanib-treated patients
was similar between the subgroups by baseline BMI and
by weight loss during the trials.
Our finding that weight loss was associated with a fas-
ter decline in FVC is consistent with a retrospective ana-
lysis of two cohorts of patients with IPF (a Japanese
cohort of 124 patients and a UK cohort of 86 patients),
which found a greater rate of FVC decline in patients
with weight loss > 5% than ≤5% over 1 year [8]. In our
analyses, weight loss > 5% over 52 weeks was also associ-
ated with a greater worsening in health-related quality of
Table 3 Adverse events (reported irrespective of causality) in subgroups of patients by BMI at baseline
BMI < 25 kg/m2 at
baseline
BMI ≥ 25 and < 30 kg/m2 at
baseline
BMI ≥ 30 kg/m2 at
baseline
Nintedanib
(n = 167)
Placebo
(n = 140)
Nintedanib
(n = 285)
Placebo
(n = 168)
Nintedanib
(n = 186)
Placebo
(n = 115)
Adverse event(s) 161 (96.4) 124 (88.6) 270 (94.7) 151 (89.9) 178 (95.7) 104 (90.4)
Most frequent adverse event(s)a
Diarrhoea 102 (61.1) 24 (17.1) 176 (61.8) 33 (19.6) 115 (61.8) 21 (18.3)
Nausea 37 (22.2) 7 (5.0) 71 (24.9) 11 (6.5) 48 (25.8) 10 (8.7)
Progression of IPFb 25 (15.0) 28 (20.0) 28 (9.8) 25 (14.9) 11 (5.9) 8 (7.0)
Nasopharyngitis 33 (19.8) 21 (15.0) 32 (11.2) 32 (19.0) 22 (11.8) 15 (13.0)
Cough 16 (9.6) 16 (11.4) 38 (13.3) 32 (19.0) 31 (16.7) 9 (7.8)
Decreased appetite 26 (15.6) 13 (9.3) 23 (8.1) 11 (6.5) 19 (10.2) 0
Vomiting 25 (15.0) 7 (5.0) 25 (8.8) 1 (0.6) 24 (12.9) 3 (2.6)
Bronchitis 12 (7.2) 8 (5.7) 32 (11.2) 20 (11.9) 23 (12.4) 17 (14.8)
Dyspnoea 9 (5.4) 14 (10.0) 23 (8.1) 19 (11.3) 17 (9.1) 15 (13.0)
Weight decreased 19 (11.4) 5 (3.6) 28 (9.8) 8 (4.8) 15 (8.1) 2 (1.7)
Upper respiratory tract infection 17 (10.2) 14 (10.0) 23 (8.1) 17 (10.1) 18 (9.7) 11 (9.6)
Fatigue 9 (5.4) 14 (10.0) 14 (4.9) 13 (7.7) 17 (9.1) 6 (5.2)
Adverse event(s) leading to treatment discontinuation 43 (25.7) 19 (13.6) 50 (17.5) 19 (11.3) 30 (16.1) 17 (14.8)
Severe adverse event(s)c 44 (26.3) 34 (24.3) 81 (28.4) 42 (25.0) 49 (26.3) 23 (20.0)
Serious adverse event(s)d 61 (36.5) 37 (26.4) 82 (28.8) 54 (32.1) 51 (27.4) 36 (31.3)
Fatal adverse event(s) 8 (4.8) 13 (9.3) 18 (6.3) 9 (5.4) 11 (5.9) 9 (7.8)
Data are n (%) of patients with ≥1 such adverse event reported over 52 weeks plus a 4-week post-treatment follow-up period. aAdverse events by MedDRA
preferred term reported in ≥10% of patients in ≥1 of the subgroups shown. bCorresponds to MedDRA term ‘IPF’, which included disease worsening and acute
exacerbations. cEvent that was incapacitating or that caused an inability to work or to perform usual activities. dEvent that resulted in death, was immediately life-
threatening, resulted in persistent or clinically significant disability or incapacity, required or prolonged hospitalisation, was related to a congenital anomaly or
birth defect, or was deemed serious for any other reason
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life assessed using the SGRQ. The reasons for this are
not clear, but it may be that this extent of weight loss re-
flects a significant worsening in a patient’s overall health
(not necessarily related to their IPF). A weight loss of 5%
is often used to define significant unintentional weight
loss and is included in the definition of cachexia [18, 19]
and in criteria for the diagnosis of malnutrition pro-
posed by a global consensus group [20].
Low BMI and low fat-free mass are common in pa-
tients with IPF [21]. Weight loss in patients with IPF
may occur due to physical inactivity [22], which leads to
loss of muscle mass, or to loss of appetite due to factors
such as symptoms, medications, malnutrition, or depres-
sion [23]. In our analyses, greater proportions of patients
who had > 5% than ≤5% weight loss during the trials had
adverse events of diarrhoea and decreased appetite (in
both the nintedanib and placebo groups). Antifibrotic
therapies (nintedanib and pirfenidone) are associated
with gastrointestinal adverse events, including diarrhoea,
nausea, and vomiting, and with loss of appetite and
weight loss [24, 25]. Almost 20% of patients in the pla-
cebo group and over a third of patients in the nintedanib
group had a weight loss > 5% over 52 weeks, highlighting
the importance of supportive care, including nutri-
tional interventions when required and measures to
avoid physical inactivity and loss of muscle mass, in
patients with this debilitating disease. In most pa-
tients, gastrointestinal effects of antifibrotic therapy
can be managed successfully with hydration and
symptomatic therapy or, if this is insufficient, by dose
adjustment [26–28].
Modelling of pharmacokinetic data from patients with
IPF treated with nintedanib showed that age, weight,
Asian race, smoking, and lactate dehydrogenase levels
have small to moderate effects on nintedanib exposure,
which are within the range of inter-patient variability
and do not warrant a priori dose adjustment [29, 30]. As
such, it is unlikely that the numerically greater effect of
nintedanib on FVC decline observed in patients with
lower BMI is explained by the higher nintedanib expos-
ure expected in this subgroup, although a contribution
of pharmacokinetics to this finding cannot be ruled out.
Previous subgroup analyses of data from the INPULSIS
trials have shown that despite Asian patients having a
lower BMI and lower FVC, there was no difference in
the effect of nintedanib on FVC decline, or the adverse
Table 4 Adverse events (reported irrespective of causality) in subgroups of patients by weight loss over 52 weeksa
Weight loss ≤ 5% Weight loss > 5%
Nintedanib (n = 397) Placebo (n = 338) Nintedanib (n = 241) Placebo (n = 85)
Adverse event(s) 376 (94.7) 297 (87.9) 233 (96.7) 82 (96.5)
Most frequent adverse event(s)b
Diarrhoea 216 (54.4) 56 (16.6) 177 (73.4) 22 (25.9)
Progression of IPFc 30 (7.6) 41 (12.1) 34 (14.1) 20 (23.5)
Dyspnoea 24 (6.0) 37 (10.9) 25 (10.4) 11 (12.9)
Nausea 90 (22.7) 20 (5.9) 66 (27.4) 8 (9.4)
Pneumonia 21 (5.3) 14 (4.1) 12 (5.0) 12 (14.1)
Nasopharyngitis 46 (11.6) 59 (17.5) 41 (17.0) 9 (10.6)
Decreased appetite 31 (7.8) 14 (4.1) 37 (15.4) 10 (11.8)
Cough 57 (14.4) 45 (13.3) 28 (11.6) 12 (14.1)
Bronchitis 43 (10.8) 33 (9.8) 24 (10.0) 12 (14.1)
Vomiting 39 (9.8) 9 (2.7) 35 (14.5) 2 (2.4)
Upper respiratory tract infection 40 (10.1) 33 (9.8) 18 (7.5) 9 (10.6)
Abdominal pain 31 (7.8) 8 (2.4) 25 (10.4) 2 (2.4)
Weight decreased 14 (3.5) 3 (0.9) 48 (19.9) 12 (14.1)
Arthralgia 8 (2.0) 12 (3.6) 6 (2.5) 9 (10.6)
Adverse event(s) leading to treatment discontinuation 72 (18.1) 38 (11.2) 51 (21.2) 17 (20.0)
Severe adverse event(s)d 94 (23.7) 72 (21.3) 80 (33.2) 27 (31.8)
Serious adverse event(s)e 97 (24.4) 86 (25.4) 97 (40.2) 41 (48.2)
Fatal adverse event(s) 20 (5.0) 25 (7.4) 17 (7.1) 6 (7.1)
Data are n (%) of patients with ≥1 such adverse event reported over 52 weeks plus a 4-week post-treatment follow-up period. aBased on the annual rate of
decline in weight. bAdverse events by MedDRA preferred term reported in ≥10% of patients in ≥1 of the subgroups shown. cCorresponds to MedDRA term ‘IPF’,
which included disease worsening and acute exacerbations. dEvent that was incapacitating or that caused an inability to work or to perform usual activities.
eEvent that resulted in death, was immediately life-threatening, resulted in persistent or clinically significant disability or incapacity, required or prolonged
hospitalisation, was related to a congenital anomaly or birth defect, or was deemed serious for any other reason
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event profile of nintedanib, between Asian and White
patients [31, 32].
Strengths of our analyses include the large sample size
(1061 patients with a diagnosis of IPF confirmed by the
investigator) and the relatively small amount of missing
data on FVC, BMI and weight loss. Our analyses also
have several limitations, including that they were post-
hoc, that the duration of follow-up was only 52 weeks,
that the reasons for weight loss could not be determined,
that there were differences between the subgroups by
BMI and weight loss beyond factors that could be ad-
justed for, and that there were too few underweight
(BMI < 18.5 kg/m2) patients (n = 8) for them to be ana-
lysed as a subgroup. While our analyses indicate poten-
tial associations between BMI or weight loss and FVC
decline, and it is possible that there are links between
weight loss and fibrotic processes, we have not demon-
strated causal relationships. The limitations of BMI and
weight loss as measures of nutritional status and general
health must be considered. Patients’ weight loss prior to
enrolment in the INPULSIS trials is unknown.
Conclusions
These analyses of data from the INPULSIS trials showed
that patients with IPF who received placebo and had a
lower BMI at baseline, or a weight loss > 5% over 52
weeks, had a greater annual rate of decline in FVC. Nin-
tedanib reduced the rate of decline in FVC both in pa-
tients with lower and higher BMI, and in patients with
and without weight loss. Active management of the ad-
verse events that may be associated with nintedanib is
important to help patients remain on therapy.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12931-020-01528-4.
Additional file 1: Supplemental Appendix 1. Statistical analyses.
Additional file 2: Supplemental Appendix 2. List of investigators [1].
Additional file 3: Supplemental Table 1. Baseline characteristics in
subgroups of patients by BMI (< 25; ≥25 to < 30; ≥30 kg/m2) at baseline.
Additional file 4: Supplemental Table 2. Outcomes in subgroups of
patients by BMI below and at least the median at baseline.
Additional file 5: Supplemental Table 3. Annual rate of decline in
FVC (mL/year) over 52 weeks in the overall trial population.
Additional file 6: Supplemental Table 4. Baseline characteristics in
subgroups of patients by weight loss ≤5 and > 5% over 52 weeks (based
on the annual rate of decline in weight).
Additional file 7: Supplemental Figure 1. Scatter plots showing the
correlation between BMI at baseline and FVC (mL) at baseline (A) and
between BMI at baseline and the rate of decline in FVC (mL/year)
assessed over 52 weeks (B).
Additional file 8: Supplemental Figure 2. Annual rate of decline in
FVC (mL/year) over 52 weeks in subgroups of patients by weight loss
over 52 weeks (based on the change from baseline in weight at week
52).
Abbreviations
BMI: Body mass index; DLco: Diffusing capacity of the lungs for carbon
monoxide; FVC: Forced vital capacity; HRCT: High-resolution computed
tomography; IPF: Idiopathic pulmonary fibrosis; MedDRA: Medical Dictionary
for Regulatory Activities; SGRQ: St. George’s Respiratory Questionnaire
Acknowledgments
Writing assistance, supported financially by Boehringer Ingelheim, was provided
by Elizabeth Ng and Wendy Morris of FleishmanHillard Fishburn, London, UK,
during the development of this manuscript. The authors meet criteria for
authorship as recommended by the International Committee of Medical
Journal Editors (ICMJE). The authors received no direct compensation for the
development of this manuscript. The authors were fully responsible for all
content and editorial decisions, had access to all data, were involved in all
stages of development and have approved the final version. Boehringer
Ingelheim was given the opportunity to review the manuscript for medical and
scientific accuracy as well as intellectual property considerations.
Authors’ contributions
SJ, BC, RT, ML, LV, WS, MQ and VC were involved in the design of the study.
WS was involved in data analysis. All authors were involved in the
interpretation of the data and in the writing and critical review of the
manuscript. All authors approved the final version.
Funding
The INPULSIS trials were funded by Boehringer Ingelheim.
Availability of data and materials
All data relevant to this analysis are included in the article or uploaded as
supplementary information.
Ethics approval and consent to participate
The clinical protocol was approved by an independent ethics committee or
institutional review board at each participating centre listed in Supplemental
Appendix 2. All patients provided written informed consent before study
entry.
Consent for publication
Not applicable.
Competing interests
SJ reports personal fees from Actelion, AIRB, AstraZeneca, Bristol-Myers
Squibb, Boehringer Ingelheim, Chiesi, Galecto, Gilead, GlaxoSmithKline, LVL,
Mundipharma, Novartis, Pfizer, Roche, and Savara-Serendex. BC reports grants
and personal fees from Boehringer Ingelheim and Roche; grants from Apellis
and MedImmune; and personal fees from AstraZeneca and Sanofi. RT has re-
ceived fees or congress invitations from Aguettant, AstraZeneca, Baxter,
Braun, Fresenius-Kabi, Lactalis, Nestlé, Nutricia, Roche, Sanofi, Servier, and
Shire. ML reports personal fees from AstraZeneca, Boehringer Ingelheim,
Fresenius-Kabi, Roche, and Siemens Healthineers. LV reports grants from
Boehringer Ingelheim. CV reports personal fees from Boehringer Ingelheim,
Hoffmann-La Roche, and Galapagos. MW reports grants and fees paid to her
institution from Boehringer Ingelheim and Hoffmann-La Roche; fees paid to
her institution from Galapagos and Respivant. MK reports grants and per-
sonal fees from Boehringer Ingelheim and Roche. WS and MQ are employees
of Boehringer Ingelheim. VC reports research grants, personal fees, and non-
financial support from Boehringer Ingelheim; personal fees from AstraZeneca,
Bayer/Merck Sharp & Dohme, Celgene, Fibrogen, Galapagos, Galecto, Novar-
tis, Sanofi, and Shionogi; and personal fees and non-financial support from
Actelion, and Roche/Promedior.
Author details
1Department of Respiratory Medicine, Competences Centre for Rare
Pulmonary Diseases, Pontchaillou Hospital, CHU Rennes, univ Rennes, Rennes
1 University, Rennes, France. 2Université de Paris, Inserm U1152, APHP,
Hôpital Bichat, Centre de reference constitutif pour les maladies pulmonaires
rares, Paris, France. 3INRA, Inserm, Univ Rennes, Nutrition Metabolisms and
Cancer, NuMeCan, Unité de Nutrition, CHU Rennes, Rennes, France.
4Department of Radiology, CHU Rennes, univ Rennes, Rennes, France. 5Univ
Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement
et travail) - UMR_S 1085, F-35000 Rennes, France. 6Pulmonology Department,
Jouneau et al. Respiratory Research          (2020) 21:312 Page 10 of 11
Hospital Universitario de La Princesa, Madrid, Spain. 7Department of
Respiratory Medicine, Erasmus MC, University Medical Centre, Rotterdam, the
Netherlands. 8Center for Interstitial and Rare Lung Diseases, Pneumology and
Respiratory Care Medicine, Thoraxklinik, University of Heidelberg, Member of
the German Center for Lung Research, Heidelberg, Germany. 9Boehringer
Ingelheim GmbH & Co. KG, Ingelheim am Rhein, Germany. 10Boehringer
Ingelheim International GmbH, Ingelheim am Rhein, Germany. 11Reference
Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Claude Bernard
University Lyon 1, Lyon, France.
Received: 6 April 2020 Accepted: 1 October 2020
References
1. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary
fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir
Crit Care Med. 2018;198(5):e44–68.
2. Kreuter M, Ehlers-Tenenbaum S, Palmowski K, et al. Impact of comorbidities
on mortality in patients with idiopathic pulmonary fibrosis. PLoS One. 2016;
11(3):e0151425.
3. Strongman H, Kausar I, Maher TM. Incidence, prevalence, and survival of
patients with idiopathic pulmonary fibrosis in the UK. Adv Ther. 2018;35(5):
724–36.
4. Paterniti MO, Bi Y, Rekić D, Wang Y, Karimi-Shah BA, Chowdhury BA. Acute
exacerbation and decline in forced vital capacity are associated with
increased mortality in idiopathic pulmonary fibrosis. Ann Am Thorac Soc.
2017;14(9):1395–402.
5. Kishaba T, Nagano H, Nei Y, Yamashiro S. Body mass index—percent forced
vital capacity—respiratory hospitalization: new staging for idiopathic
pulmonary fibrosis patients. J Thorac Dis. 2016;8(12):3596–604.
6. Alakhras M, Decker PA, Nadrous HF, Collazo-Clavell M, Ryu JH. Body mass
index and mortality in patients with idiopathic pulmonary fibrosis. Chest.
2007;131(5):1448–53.
7. Mogulkoc N, Sterclova M, Müller V, et al. Does body mass index have
prognostic significance for patients with idiopathic pulmonary fibrosis? Eur
Respir J. 2018;52(Suppl. 62):PA2210.
8. Nakatsuka Y, Handa T, Kokosi M, et al. The clinical significance of body
weight loss in idiopathic pulmonary fibrosis patients. Respiration. 2018;96(4):
338–47.
9. Kulkarni T, Yuan K, Tran-Nguyen TK, et al. Decrements of body mass index
are associated with poor outcomes of idiopathic pulmonary fibrosis
patients. PLoS One. 2019;14(10):e0221905.
10. Nishiyama O, Yamazaki R, Sano H, et al. Fat-free mass index predicts survival
in patients with idiopathic pulmonary fibrosis. Respirology. 2017;22(3):480–5.
11. Doubková M, Švancara J, Svoboda M, et al. EMPIRE registry, Czech part:
impact of demographics, pulmonary function and HRCT on survival and
clinical course in idiopathic pulmonary fibrosis. Clin Respir J. 2018;12(4):
1526–35.
12. Snyder L, Neely ML, Hellkamp AS, et al. Predictors of death or lung
transplant in patients with IPF: data from the IPF-PRO registry. Respir Res.
2019;20(1):105.
13. Womack CJ, Harris DL, Katzel LI, Hagberg JM, Bleecker ER, Goldberg AP.
Weight loss, not aerobic exercise, improves pulmonary function in older
obese men. J Gerontol A Biol Sci Med Sci. 2000;55(8):M453–7.
14. Fenger RV, Gonzalez-Quintela A, Vidal C, et al. The longitudinal relationship
of changes of adiposity to changes in pulmonary function and risk of
asthma in a general adult population. BMC Pulm Med. 2014;14:208.
15. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in
idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–82.
16. Costabel U, Inoue Y, Richeldi L, et al. Efficacy of nintedanib in idiopathic
pulmonary fibrosis across prespecified subgroups in INPULSIS. Am J Respir
Crit Care Med. 2016;193(2):178–85.
17. Jones PW, Quirk FH, Baveystock CM. The St. George’s Respiratory
Questionnaire. Respir Med. 1991;85(Suppl B):25–31.
18. Evans WJ, Morley JE, Argilés J, et al. Cachexia: a new definition. Clin Nutr.
2008;27(6):793–9.
19. Wong CJ. Involuntary weight loss. Med Clin North Am. 2014;98(3):625–43.
20. Cederholm T, Jensen GL, Correia MITD, et al. GLIM criteria for the diagnosis
of malnutrition - a consensus report from the global clinical nutrition
community. Clin Nutr. 2019;38(1):1–9.
21. Jouneau S, Kerjouan M, Rousseau C, et al. What are the best indicators to
assess malnutrition in idiopathic pulmonary fibrosis patients? A cross-
sectional study in a referral center. Nutrition. 2019;62:115–21.
22. Bahmer T, Kirsten AM, Waschki B, et al. Prognosis and longitudinal changes
of physical activity in idiopathic pulmonary fibrosis. BMC Pulm Med. 2017;
17(1):104.
23. Akhtar AA, Ali MA, Smith RP. Depression in patients with idiopathic
pulmonary fibrosis. Chron Respir Dis. 2013;10(3):127–33.
24. Lancaster L, Albera C, Bradford WZ, et al. Safety of pirfenidone in patients
with idiopathic pulmonary fibrosis: integrated analysis of cumulative data
from 5 clinical trials. BMJ Open Respir Res. 2016;3(1):e000105.
25. Lancaster L, Crestani B, Hernandez P, et al. Safety and survival data in
patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled
data from six clinical trials. BMJ Open Respir Res. 2019;6(1):e000397.
26. Corte T, Bonella F, Crestani B, et al. Safety, tolerability and appropriate use of
nintedanib in idiopathic pulmonary fibrosis. Respir Res. 2015;16:116.
27. Lancaster LH, de Andrade JA, Zibrak JD, et al. Pirfenidone safety and
adverse event management in idiopathic pulmonary fibrosis. Eur Respir Rev.
2017;26(146):170057.
28. Bendstrup E, Wuyts W, Alfaro T, et al. Nintedanib in idiopathic pulmonary
fibrosis: practical management recommendations for potential adverse
events. Respiration. 2019;97(2):73–184.
29. Schmid U, Doege C, Dallinger C, Freiwald M. Population pharmacokinetics
of nintedanib in patients with idiopathic pulmonary fibrosis. Pulm
Pharmacol Ther. 2018;48:136–43.
30. Wind S, Schmid U. Freiwald, et al. clinical pharmacokinetics and
pharmacodynamics of nintedanib. Clin Pharmacokinet. 2019;58(9):1131–47.
31. Taniguchi H, Xu Z, Azuma A, et al. Subgroup analysis of Asian patients in
the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis.
Respirology. 2016;21(8):1425–30.
32. Xu Z, Li H, Wen F, et al. Subgroup analysis for Chinese patients included in
the INPULSIS trials on nintedanib in idiopathic pulmonary fibrosis. Adv Ther.
2019;36(3):621–31.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Jouneau et al. Respiratory Research          (2020) 21:312 Page 11 of 11
